Potential adverse effects of discontinuing psychotropic drugs: Part 2: Antidepressant drugs

Journal of Psychosocial Nursing and Mental Health Services

Volumn 48, Issue 7, 2010, Pages 9-12

  Howland, Robert H ^a  

^a UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 77954671870     PISSN: 02793695     EISSN: None     Source Type: Journal    
DOI: 10.3928/02793695-20100527-98     Document Type: Article

References (10)

1. Andrade, C. (2004). Antidepressant-withdrawal mania: A critical review and synthesis of the literature. Journal of Clinical Psychiatry, 65, 987-993.
2. Baldessarini, R.J., Tondo, L., Ghiani, C., & Lepri, B. (2010). Illness risk following rapid versus gradual discontinuation of antidepressants. American Journal of Psychiatry. Advance online publication. doi:10.1176/appi.ajp.2010.09060880
3. Brunton, L.L., Lazo, J.S., Parker, K.L., Buxton, I.L.O., & Blumenthal, D. (Eds.). (2006). Goodman & Gilman's the pharmacological basis of therapeutics(11th ed.). New York: McGraw-Hill.
4. Haddad. P. (1998). The SSRI discontinuation syndrome. Journal of Psychopharmacology, 12, 305-313.
5. Markowitz, J.S., & Patrick, K.S. (1998). Venlafaxine-tramadol similarities. Medical Hypotheses, 51, 167-168.
6. Muzina, D.J. (2010). Discontinuing an antidepressant? Tapering tips to ease distressing symptoms. Current Psychiatry, 9(3). Retrieved from http://www.currentpsychiatry.com/article_pages.asp?AID=8415&UID=
7. Puozzo, C., Panconi, E., & Deprez, D. (2002). Pharmacology and pharmacokinetics of milnacipran. International Clinical Psychopharmacology, 17(Suppl. 1), S25-S35.
8. Sadock, B.J., Sadock, V.A., & Sussman, N. (2006). Kaplan & Sadock's pocket handbook of psychiatric drug treatment (4th ed.). Philadelphia: Lippincott Williams & Wilkins.
9. Schatzberg, A.F., Cole, J.O., & DeBattista, C. (2007). Manual of clinical psychopharmacology (6th ed.). Arlington, VA: American Psychiatric Publishing.
10. Stock, M.J. (1997). Sibutramine: A review of the pharmacology of a novel anti-obesity agent. International Journal of Obesity and Related Metabolic Disorders, 21(Suppl. 1), S25-S29.